Skip to main content
SpringerLink
Log in

Is pharmacoeconomic analysis relevant in formulary decision-making?

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Johnson JA, Friesen E. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions. Pharmacoeconomics 1998 May; 13 (5 Pt 1): 479–85

    Article  PubMed  CAS  Google Scholar 

  2. Mason J. The generalisability of pharmacoeconomic studies. Pharmacoeconomics 1997; 11(6): 503–14

    Article  PubMed  CAS  Google Scholar 

  3. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995; 4: 355–71

    Article  PubMed  CAS  Google Scholar 

  4. Armstrong EP, Langley PC. Disease management programs. Am J Health Syst Pharm 1996; 53: 53–8

    PubMed  CAS  Google Scholar 

  5. Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

    Google Scholar 

  6. O’Brien B. Economic evaluation of pharmaceuticals: Frankenstein’s monster or vampire of trials? Med Care 1996; 34 (12 Suppl.): DS99–108

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Is pharmacoeconomic analysis relevant in formulary decision-making?. Drugs Ther. Perspect 12, 14–16 (1998). https://doi.org/10.2165/00042310-199812090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199812090-00005

Keywords

Search

Navigation